MG Biologics
- Company typePrivate
- Founded1999
- HeadquartersAmes, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
MG Biologics firmographics
Firmographics- Name
- MG Biologics
- Legal name
- MG Biologics
- Website
- https://mgbiologics.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
MG Biologics industry classification
Industry- Product category
- Veterinary Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)
- akta.pro secondary industries
- Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Equine Therapeutics (Rx) (HLAMAEAC)
Keywords
Where MG Biologics is headquartered
LocationHeadquarters
- HQ city
- Ames
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MG Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Plasma and Antibody Products: One-time sale of plasma products (equine, canine, bovine, porcine) including USDA licensed products like ReSolution Rhodococcus Equi Antibody and High-Glo Equine IgG. Products sold directly and through distribution partners.
- Rattler Antivenom: One-time sale of polyvalent antivenom for Crotalidae snakebites in canine, equine, and feline. Licensed product with three-year shelf life, sold in 50ml treatments.
- Custom Blend Plasma: Custom designed ImmunoGlo plasma blends tailored to individual farm/farm veterinarian specifications. Pricing directly related to quantity per unit.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
MG Biologics product offering
Product offeringCore offering
MG Biologics is a USDA-licensed plasma and antibody manufacturer based in Ames, Iowa, that produces hyperimmune plasma products, IgG formulations, and polyvalent antivenom for veterinary use across equine, canine, bovine, porcine, and feline species. The company collects equine plasma from specifically vaccinated donors and manufactures biological products that deliver targeted antibodies to treat or prevent conditions such as Rhodococcus equi pneumonia, Failure of Passive Transfer in foals, Clostridium infections, enteric diseases, and pit viper envenomation.
Product overview
MG Biologics is a USDA-licensed plasma and antibody manufacturer located in Ames, Iowa, offering a comprehensive portfolio of biological products for animal health. The product line centers on plasma-derived antibodies and antivenom products across multiple species including equine, canine, bovine, porcine, and feline. Key products include the ReSolution Rhodococcus Equi Antibody and High-Glo Equine IgG (both USDA licensed), the Rattler Antivenom polyvalent antivenom, TetriCare for tetanus protection, ACDCare for Clostridium perfringens coverage, Immunogut for canine enteric support, and AbSolution PG for porcine use. The ImmunoGlo Custom Blends platform allows veterinarians to design custom plasma formulations by selecting specific donor vaccination histories. Products range from single-pathogen plasmas to complex multi-pathogen blends available in volumes from 50ml to 1500ml.
Differentiator
Problem solved
Functional benefit
Brands
- ImmunoGlo: Custom blended plasma product line for equine use, allowing veterinarians to design donor vaccination histories.
- ReSolution
- High-Glo
- TetriCare
- ACDCare
- AbSolution PG
- Rattler Antivenom
- Immunogut
Products and services
- ReSolution Rhodococcus Equi Antibody USDA-licensed plasma product containing Virulence-Associated Plasmid A (VapA) antibodies with a minimum release titer of 1:10,000, used by veterinarians for prevention and control of Rhodococcus equi pneumonia in foals.
- High-Glo Equine IgG USDA-licensed intravenous treatment for Failure of Passive Transfer (FPT) in neonatal foals, supplementing IgG through plasma rich in immunoglobulin antibodies.
- Rattler Antivenom Antivenom Crotalidae Polyvalent Equine Origin that neutralizes venom from rattlesnakes, copperheads, and cottonmouths/water moccasins including Mohave Venom A. Licensed for canine, equine, and feline use with a three-year shelf life.
- TetriCare Plasma from donors vaccinated against tetanus toxin for wound care management in cattle, horses, goats, sheep, and swine, available in 50 mL bottle and 200 mL IV bag formats.
- ACDCare Plasma from donors vaccinated against Clostridium perfringens Types A, C & D for cattle, goats, sheep, and swine, supporting gastrointestinal tract during high-stress situations.
- Immunogut Orally administered plasma from donors vaccinated against E. coli, Parvovirus, Salmonella, and Clostridioides difficile for canine support during enteric distress and high-stress situations.
- AbSolution PG Plasma from donors vaccinated against Clostridium difficile for porcine use to support intestinal health.
- ImmunoGlo Custom Blends Custom blended equine plasma where veterinarians can choose donor vaccination histories (R. equi, S. equi, Rotavirus, C. difficile, C. perfringens A, Salmonella, E. coli, West Nile Virus, C. botulinum B) and volumes from 900 to 1500 milliliters per unit.
- Protein Volume Replacement PVR Lowest cost plasma option for hypoproteinemia or hypovolemic critical care patients containing 30g albumin and 60g total protein per unit for pre and post operative protein replacement.
Quantifiable outcome
- 80% protection against R. equi pneumonia with 2L hyperimmune plasma vs 68% with 1L
- +4 more outcomes
Companies that use MG Biologics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles4 records
MG Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MG Biologics partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered primary, core and notable.
- VetcoveprimaryMG Biologics moved e-commerce operations to Vetcove platform, enabling free access to a progressive veterinary e-commerce platform. Customers can search products by name or company name on Vetcove. Over 8,000 veterinary hospitals use Vetcove for inventory management and purchasing.
- MWI Veterinary SupplycoreDistribution partner for MG Biologics products including Rattler Antivenom. Part of the distribution network providing products to veterinary clinics.
- Patterson VeterinarycoreDistribution partner for MG Biologics products. Provides veterinary supply distribution services.
- Midwest Veterinary SupplycoreDistribution partner for MG Biologics products including Rattler Antivenom.
- Animal Health InternationalcoreDistribution partner for MG Biologics products.
- CovetruscoreDistribution partner for MG Biologics products available through Vetcove platform integration.
- VetOnecoreVetOne distributes Rattler Antivenom. Online purchasing available through VetOne store.
- Texas A&M University (Gluck Equine Research Center)notableTexas A&M published research in 2016 and 2019 on Rhodococcus equi hyperimmune plasma. The Gluck Equine Research Center conducted third-party studies comparing commercial R. equi antibody products, finding ReSolution showed 4x higher VapA-specific IgGa than competitors.
- Oklahoma State UniversitynotableOklahoma State University conducted research on antivenom effectiveness using mouse model to test neutralization of North American rattlesnake venoms.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
MG Biologics competitors and assessment
Company assessmentDirect peers
- Plasvacc USA: Plasvacc USA is a direct competitor producing hyperimmune plasma products for veterinary use, particularly equine Rhodococcus equi antibody products. Highly comparable in product category, manufacturing approach (equine plasma), and target customer base of equine veterinarians.
- Lake Immunogenics: Lake Immunogenics produces hyperimmune equine plasma products for the veterinary market, including Rhodococcus equi antibody formulations. Closely comparable in plasma-derived antibody manufacturing for equine neonatal care, directly competing on the same product category.
- Colorado Serum Company: Colorado Serum Company manufactures veterinary biologics including antivenoms and plasma-derived products for animal health. Comparable as a USDA-licensed manufacturer of biologics (especially antivenoms) serving similar veterinary channels.
- Midland BioProducts: Midland BioProducts produces plasma-derived and biologics products for veterinary use, including equine plasma. Comparable as a peer-sized veterinary biologics manufacturer competing in the same equine plasma and antibody categories.
Broad incumbents
- Bimeda: Bimeda is a global veterinary pharmaceuticals manufacturer with a broad animal health portfolio including biologics and plasma-derived products. Comparable as a broader incumbent operating in veterinary pharmaceuticals with overlapping product categories.
- Zoetis: Zoetis is the world's largest animal health company with a broad portfolio including vaccines, parasiticides, and biologics. Comparable as a broad incumbent in animal health that could expand into hyperimmune plasma/equine biologics segments, though it does not currently focus on equine plasma products.
- Boehringer Ingelheim Vetmedica (BIVI): BIVI is a major veterinary pharmaceuticals and biologics manufacturer with equine products including Rhodococcus equi vaccines and treatments. Comparable as a broad incumbent with overlapping interest in equine respiratory disease and broader veterinary biologics.
- Vetoquinol: Vetoquinol is a global veterinary pharmaceutical company with products across companion animal and livestock categories, including biologics. Comparable as a broader veterinary pharmaceuticals incumbent that operates in overlapping distribution channels.
- Dechra Pharmaceuticals: Dechra is a specialty veterinary pharmaceuticals company with a strong equine and companion animal focus. Comparable as a specialty veterinary pharma incumbent serving similar equine and small animal veterinary channels with biologics and therapeutics.
Emerging players
- VetStem Biopharma: VetStem Biopharma is an emerging regenerative medicine and biologic therapy company in veterinary medicine. Comparable as a smaller, emerging biologics-focused veterinary company that could potentially overlap or expand into adjacent biologic categories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MG Biologics social profiles
Digital presenceMG Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MG Biologics leadership team
Management profileNumber of profiles
Profiles2 records
MG Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MG Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MG Biologics
What does MG Biologics do?
MG Biologics is a USDA-licensed plasma and antibody manufacturer based in Ames, Iowa, that produces hyperimmune plasma products, IgG formulations, and polyvalent antivenom for veterinary use across equine, canine, bovine, porcine, and feline species. The company collects equine plasma from specifically vaccinated donors and manufactures biological products that deliver targeted antibodies to treat or prevent conditions such as Rhodococcus equi pneumonia, Failure of Passive Transfer in foals, Clostridium infections, enteric diseases, and pit viper envenomation.
Is MG Biologics a public or private company?
MG Biologics is a private company. It is classified as family owned and is currently operating.
When was MG Biologics founded?
MG Biologics was founded in 1999. It employs 11 to 50 people.
Where is MG Biologics based?
MG Biologics is headquartered in Ames, United States, in the North America region.
How does MG Biologics make money?
Three revenue lines are on record. Plasma and Antibody Products are the primary driver. The others are rattler Antivenom and custom Blend Plasma.
Who are MG Biologics's main competitors?
Direct peers on record are Plasvacc USA, Lake Immunogenics, Colorado Serum Company and Midland BioProducts. Broad incumbents are Bimeda, Zoetis, Boehringer Ingelheim Vetmedica (BIVI), Vetoquinol and Dechra Pharmaceuticals. VetStem Biopharma is listed as an emerging player.
Does MG Biologics have an API?
No public API is recorded for MG Biologics.
What industry is MG Biologics in?
MG Biologics's product category is Veterinary Biologics. Its primary akta.pro industry code is HLAMAEAK, Biologics & Immunotherapies (Non-vaccine), with a secondary code of HLAMAEAB, Livestock & Production Animal Therapeutics (Rx). Its NAICS code is 325414 and its SIC code is 2836.